ICURe TopMD Pathway Biomarker Catalogue

在这个项目中，我们正在开发一个跨越疾病和治疗的新的、更强大和信息更丰富的生物标记物目录，用于作为辅助诊断来预测个别患者的治疗反应，并提高药物开发和测试的效率。我们的人工智能增强技术TopMD是由该大学开发的，创新性地使用已知的生物途径作为坐标来测量全球基因表达的“形状”，准确地表示分子表型作为一个强大的“途径生物标记物”。与制药公司和医疗保健提供者的讨论确定了进入市场的途径，以最大化这项创新技术所承诺的价值。我们得到了创新英国ICURE市场验证计划Options环形交叉路口的专家小组的建议，以‘剥离’一家公司，并创建一个TopMD途径生物标记物库作为生物标记物产品的网络目录。这个项目将提供疾病和治疗诱导基因表达的TopMD途径生物标记物的库。TopMD疾病分类诊断和亚型诊断的准确性将通过同行评审进行评估和公布。这些图书馆将作为“路径生物标记物”的高价值目录，将TopMD定位为精密医学领域的全球领先者，并应对政府的2/4重大挑战；人工智能与数据和健康老龄化。

In this project, we are developing a catalogue, across diseases and treatments, of new, more powerful and informative biomarkers for use as companion diagnostics to predict treatment response in individual patients and for improving the efficiency of the development and testing of medicines.Our AI-enhanced technology, TopMD, was developed at the University, innovatively uses known biological pathways as coordinates for measuring the 'shape' of global gene expression, accurately representing both the molecular phenotype as a robust 'pathway biomarker'.Discussions with pharmaceutical companies and healthcare providers identified routes to market to maximise the value promised by this innovative technology. We were advised by a panel of experts at the Innovate UK ICURe market validation programme options roundabout to 'spin-out' a company, and create a library of TopMD pathway biomarkers as a networked catalogue of biomarker products.This project will deliver libraries of TopMD pathway biomarkers of disease and treatment-induced gene expression. The accuracy of TopMD classification diagnosis of diseases and disease sub-types will be assessed and published via peer review. The libraries will act as high value catalogues of 'pathway biomarkers', positioning TopMD as a global leader in Precision Medicine and meeting 2/4 of the government grand challenges; AI & Data and Healthy ageing.